CN113288969A - 一种治疗支气管炎的药物及其制备方法 - Google Patents
一种治疗支气管炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN113288969A CN113288969A CN202110673933.7A CN202110673933A CN113288969A CN 113288969 A CN113288969 A CN 113288969A CN 202110673933 A CN202110673933 A CN 202110673933A CN 113288969 A CN113288969 A CN 113288969A
- Authority
- CN
- China
- Prior art keywords
- parts
- tablets
- medicine
- tablet
- oxytetracycline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请提供了一种治疗支气管炎的药物及其制备方法,包含以下重量份的原药甘草浸膏粉8~12份,马来酸氯苯那敏0.1~0.3份,富马酸酮替芬0.068~0.1份,醋酸泼尼松0.18~0.32份,氨茶碱2.5~4.1份,土霉素6.5~8.6份,盐酸二氧丙嗪0.2~0.4份,川贝母25~35份,知母24~31份,半夏9~19份,百药煎19~26份,紫菀14~26份。取相应重量份数的中药经熬制、浓缩,再加入西药粉末,然后按照药学常规加工方法制成片剂、颗粒剂、丸剂或胶囊等剂型,即可得到所述的一种治疗支气管炎的药物。本申请创造性地将中药与西药两者配合使用,以宣肺解表,止咳化痰,平喘。本申请所采用的药材药源易得,成本低廉,减轻患者负担,无毒副作用。
Description
技术领域
本申请涉及医药技术领域,尤其涉及到一种治疗支气管炎的药物及其制备方法。
背景技术
慢性支气管炎是气管、支气管黏膜及周围组织的慢性非特异性炎症,临床以咳嗽、咳痰为主要症状;急性支气管炎是由于生物性或非生物性致病因素引起的支气管树黏膜急性炎症,急性支气管炎在小孩和老年人中多见,多为上呼吸道病毒感染引起,受凉为主要原因,秋冬为急性支气管炎的多发季节;在流感流行时,急性支气管炎的发生率更高。
目前西医治疗多使用抗生素类药物,抗生素类药物具有消炎效果快的优点,但是经过世界各国科学家证实,长期使用抗生素会产生严重的耐药性,最后会导致很多抗生素类药物失效,炎症类疾病越来越难以治愈;而近年来出现的一些纯中药的药物,只能暂时控制症状的作用,仍然不能彻底治愈病症。
发明内容
针对现有技术的不足,本申请的目的就在于提供一种治疗支气管炎的药物及其制备方法,其以甘草浸膏粉、马来酸氯苯那敏、富马酸酮替芬、醋酸泼尼松、氨茶碱、土霉素、盐酸二氧丙嗪、川贝母、知母、半夏、百药煎、紫菀等为原料加工而成,能治疗急性支气管炎、慢性支气管炎,可以久服,疗效确切且无毒副作用。
本申请采用的技术方案如下:
一种治疗支气管炎的药物,包含以下重量份的原药:甘草浸膏粉8~12份,马来酸氯苯那敏0.1~0.3份,富马酸酮替芬0.068~0.1份,醋酸泼尼松0.18~0.32份,氨茶碱2.5~4.1份,土霉素6.5~8.6份,盐酸二氧丙嗪0.2~0.4份,川贝母25~35份,知母24~31份,半夏9~19份,百药煎19~26份,紫菀14~26份。
进一步地,一种治疗支气管炎的药物,包含以下重量份的原药:甘草浸膏粉10份,马来酸氯苯那敏0.24份,富马酸酮替芬0.08份,醋酸泼尼松0.25份,氨茶碱3.2份,土霉素7.1份,盐酸二氧丙嗪0.3份,川贝母30份,知母27份,半夏16份,百药煎23份,紫菀18份。
进一步地,一种治疗支气管炎的药物,包含以下重量份的原药:甘草浸膏粉11份,马来酸氯苯那敏0.19份,富马酸酮替芬0.088份,醋酸泼尼松0.25份,氨茶碱3.7份,土霉素7.8份,盐酸二氧丙嗪0.3份,川贝母33份,知母29份,半夏13份,百药煎20份,紫菀22份。
进一步地,一种治疗支气管炎的药物,所述马来酸氯苯那敏采用市售产品马来酸氯苯那敏片;所述富马酸酮替芬采用市售产品富马酸酮替芬片;所述醋酸泼尼松采用市售产品醋酸泼尼松片;所述氨茶碱采用市售产品氨茶碱片;所述土霉素采用市售产品土霉素片;所述盐酸二氧丙嗪采用市售产品盐酸二氧丙嗪片。
进一步地,所述百药煎为五倍子同茶叶经发酵制成的块状物。
进一步地,一种治疗支气管炎的药物的制备方法,包括以下步骤:
(1)称取相应份量的马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母、知母、半夏、百药煎、紫菀;
(2)将复方甘草片、马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母,放入超微粉碎机中研磨20min后,用200目筛网筛分,得到原料粉末;
(3)将知母、半夏、百药煎、紫菀加入砂锅中,加入水1~2L,加热至沸腾,保持沸腾15min,得到混合液;
(4)将步骤(3)得到的混合液过滤浓缩,得到浓缩液体;
(5)将步骤(2)得到的原料粉末和甘草浸膏粉加入浓缩液体中,混匀;然后按照药学常规加工方法制成片剂、颗粒剂、丸剂或胶囊等剂型,得到用于治疗支气管炎的药物。
进一步地,一种治疗支气管炎的药物的服用方法,服用方法为饭前或饭后服用,成人每次服用量相当于生药量0.5~1g。
本申请的有益效果在于:
(1)本申请一种治疗支气管炎的药物,用于治疗感冒引起的急性支气管炎、慢性支气管炎急性发作等;本申请的药物原料包含中药和西药成分,所采用的西药皆为普通市售药品,成本低廉;所采用的中药材,药源易得,成本低廉,减轻患者负担,无毒副作用,符合中医药原则和感冒引起的急性支气管炎、慢性支气管炎急性发作患者病理特点。
(2)本申请创造性地将中药与西药两者配合使用,以宣肺解表,止咳化痰,平喘,并以合适的制备工艺,其治疗效果大幅度提高,突破了常规观念,取得了预想不到的疗效。
(3)本申请的药物原料经过熬制浓缩,可以制备为片剂、颗粒剂、丸剂或胶囊等剂型,方便服用。
具体实施方式
下面将结合本申请实施例,对本申请实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本申请一部分实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本申请保护的范围。
实施例一
一种治疗支气管炎的药物,由下列重量份配比的原料制成:甘草浸膏粉10份,马来酸氯苯那敏0.24份,富马酸酮替芬0.08份,醋酸泼尼松0.25份,氨茶碱3.2份,土霉素7.1份,盐酸二氧丙嗪0.3份,川贝母30份,知母27份,半夏16份,百药煎23份,紫菀18份。其制备方法包括以下步骤:
(1)根据份量称取马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片和盐酸二氧丙嗪片;称取川贝母30g、知母27g、半夏16g、百药煎23g、紫菀18g;
(2)将复方甘草片、马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母,放入超微粉碎机中研磨20min后,用200目筛网筛分,得到原料粉末;
(3)将知母、半夏、百药煎、紫菀加入砂锅中,加入水1.2L,加热至沸腾,保持沸腾15min,得到混合液;
(4)将步骤(3)得到的混合液过滤浓缩,得到浓缩液体;
(5)将步骤(2)得到的原料粉末和甘草浸膏粉加入浓缩液体中,混匀;然后按照药学常规加工方法添加辅料,并制成片剂,每片药物含量相当于生药量0.6g。
实施例二
一种治疗支气管炎的药物,由下列重量份配比的原料制成:甘草浸膏粉11份,马来酸氯苯那敏0.19份,富马酸酮替芬0.088份,醋酸泼尼松0.25份,氨茶碱3.7份,土霉素7.8份,盐酸二氧丙嗪0.3份,川贝母33份,知母29份,半夏13份,百药煎20份,紫菀22份。其制备方法包括以下步骤:
(1)根据份量称取马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片和盐酸二氧丙嗪片;称取川贝母33g、知母29g、半夏13g、百药煎20g、紫菀22g;
(2)将复方甘草片、马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母,放入超微粉碎机中研磨20min后,用200目筛网筛分,得到原料粉末;
(3)将知母、半夏、百药煎、紫菀加入砂锅中,加入水1.3L,加热至沸腾,保持沸腾15min,得到混合液;
(4)将步骤(3)得到的混合液过滤浓缩,得到浓缩液体;
(5)将步骤(2)得到的原料粉末和甘草浸膏粉加入浓缩液体中,混匀;然后按照药学常规加工方法添加辅料,并制成胶囊,每颗胶囊药物含量相当于生药量0.6g。
药效试验
1、选取实施例1、2制备的药物,进行临床试验。
按照平行、随机、对照实验设计方案,严格设立对照组,观测服用实施例1、2制备的药物的临床疗效。
2、病理选择
急性支气管、慢性气管炎急性发作或继发肺部感染的诊断标准:(1)急性支气管炎以咳、喘、痰为主要症状;(2)慢性气管炎急性发作是指咳、喘、痰三症或三者之一。(3)排除肺结核、各种心脏病或风寒、肾虚、痰湿引起的可痰喘症状。中医辨证的诊断标准:(1)风热或风寒化热型:咳嗽痰稠,咳而不爽,口渴咽干痛,热,甚至气逆而喘,或见头痛,恶心有汗等表征,苔薄黄,脉浮数。(2)痰热型:痰黄粘稠,胸满气阻,渴喜冷饮,小便黄,大便秘,发热或不发热,苔黄或白黄,脉弦滑或数。(3)热哮:呼吸急促、喉中哮鸣、胸高气粗急促、咳呛阵作、痰黄胶粘、排吐不利、胸膈烦闷不安、面赤自汗、口渴喜饮、舌质红、苔黄腻、脉滑数。
试验病理标准:
纳入病例:凡西医诊断符合“急性支气管、慢性气管炎急性发作或继发肺部感染”诊断标准且属于中医辨证符合风热或风寒化热型、痰热型和热哮的成年者,年龄18~75岁之间,知情同意的患者可以纳入试验病例。
排除病例:(1)病情急性加重期的病人;(2)中医辨证不属于风热或风寒化热型、痰热型和热哮的患者;(3)年龄在18岁以下,75岁以上者,孕妇或哺乳期妇女,对本药过敏者;(4)重度心力衰竭、心功能属于IV级者不宜纳入试验病例;(6)凡不符合纳入标准、未按规定用药、无法判断疗效或资料不全影响疗效判断者。
3、试验方法
分组方法:采用随机、对照实验进行观察,对上述纳入试验病例采用随机对照分组方法,在随机表上查出治疗组和对照组,并确保两组病例在性别、年龄、病程等方面接近。总病例数360例,四个治疗组各60例,两个对照组60例。
4、治疗方法
(1)治疗组:基础治疗同对照组,同时服用实施例1、或实施例2制备的药物,口服治疗,用法,每次1片或1颗,日服两次,疗程三个月,随访1年。
(2)对照组:
患者给予清肺消炎丸口服,每日两次,每次60丸,疗程三个月,随访1年。
病人如遇急性加重,给予急性发作期常规处理。
5、疗效评定标准
(1)痊愈;疗程终了时症状及体征基本消失;
(2)显效:病情以重度变为轻度,或中度、轻度的症状及体征有显著好转;
(3)有效:病情以重度变为中度,或由中度变为轻度,或主诉症状好转,体征无明显改善。
(4)无效:症状及体征皆无改善或加重。
6、治疗结果见表1
表1治疗结果表
由上表可知,本申请药物疗效确切,总有效率在95%以上。经临床观察表明:本申请药物对于治疗感冒引起的急性支气管炎、慢性支气管炎急性发作疗效显著,均优于对照组,且起效迅速。应用本申请的药物治疗慢性支气管炎,治疗效果好,起效迅速,无明显毒副作用,充分体现了本申请将中药与西药两者配合使用,所取得的预想不到的疗效。
典型病例:
韩某某,男,60岁,巩义市小王沟人,该患者于2011年因感冒发烧、咽痛、咳嗽、吐痰,在家门口小诊所服药治疗效果不佳,随后自觉症状加重,感觉胸闷,晚上咳嗽不能平躺,经胸片检查,显示肺纹理紊乱,阻塞性肺气肿合并感染,体温37度,多日来患者精神较差,食欲睡眠欠佳,晚上咳嗽加剧,有时吐清白痰,有时黄稠痰,大小便尚正常。病人体胖,无心脏病,糖尿病史,无肝炎,无结核史,无过敏史,血压120/80毫米汞柱。后来我诊所求诊,随让服用本申请实施例1药物,一次0.6克,一日两次,早晚各服一次,服用一天效果明显,第二天几乎不咳,共治疗一个疗程,随访2年,无复发。
刘某,女,38岁,家住巩义市庄头村,2010年因生小孩受凉咳嗽,吐痰,咽痒不爽,经人介绍来我门诊就医。病人体温正常,血压110/75毫米汞柱,咳白黏痰,早晚咳嗽明显,大小便正常,饮食正常,听诊后确诊为支气管炎,随让其服用本申请实施例2药物,一次0.6克,一日二次,服用两天就明显减轻,共治疗2个疗程,随访1年,无复发。
以上所述仅为本申请的较佳实施例而已,并不用以限制本申请,凡依本申请范围所做的均等变化与修饰,皆应属本申请的涵盖范围。此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (7)
1.一种治疗支气管炎的药物,其特征在于:包含以下重量份的原药:甘草浸膏粉8~12份,马来酸氯苯那敏0.1~0.3份,富马酸酮替芬0.068~0.1份,醋酸泼尼松0.18~0.32份,氨茶碱2.5~4.1份,土霉素6.5~8.6份,盐酸二氧丙嗪0.2~0.4份,川贝母25~35份,知母24~31份,半夏9~19份,百药煎19~26份,紫菀14~26份。
2.如权利要求1所述的一种治疗支气管炎的药物,其特征在于:包含以下重量份的原药:甘草浸膏粉10份,马来酸氯苯那敏0.24份,富马酸酮替芬0.08份,醋酸泼尼松0.25份,氨茶碱3.2份,土霉素7.1份,盐酸二氧丙嗪0.3份,川贝母30份,知母27份,半夏16份,百药煎23份,紫菀18份。
3.如权利要求1所述的一种治疗支气管炎的药物,其特征在于:包含以下重量份的原药:甘草浸膏粉11份,马来酸氯苯那敏0.19份,富马酸酮替芬0.088份,醋酸泼尼松0.25份,氨茶碱3.7份,土霉素7.8份,盐酸二氧丙嗪0.3份,川贝母33份,知母29份,半夏13份,百药煎20份,紫菀22份。
4.如权利要求1所述的一种治疗支气管炎的药物,其特征在于:所述马来酸氯苯那敏采用市售产品马来酸氯苯那敏片;所述富马酸酮替芬采用市售产品富马酸酮替芬片;所述醋酸泼尼松采用市售产品醋酸泼尼松片;所述氨茶碱采用市售产品氨茶碱片;所述土霉素采用市售产品土霉素片;所述盐酸二氧丙嗪采用市售产品盐酸二氧丙嗪片。
5.如权利要求1所述的一种治疗支气管炎的药物,其特征在于:所述百药煎为五倍子同茶叶经发酵制成的块状物。
6.如权利要求1或4所述的一种治疗支气管炎的药物的制备方法,其特征在于:包括以下步骤:
(1)称取相应份量的马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母、知母、半夏、百药煎、紫菀;
(2)将马来酸氯苯那敏片、富马酸酮替芬片、醋酸泼尼松片、氨茶碱片、土霉素片、盐酸二氧丙嗪片、川贝母,放入超微粉碎机中研磨20min后,用200目筛网筛分,得到原料粉末;
(3)将知母、半夏、百药煎、紫菀加入砂锅中,加入水1~2L,加热至沸腾,保持沸腾15min,得到混合液;
(4)将步骤(3)得到的混合液过滤浓缩,得到浓缩液体;
(5)将步骤(2)得到的原料粉末和甘草浸膏粉加入浓缩液体中,混匀;然后按照药学常规加工方法制成片剂、颗粒剂、丸剂或胶囊等剂型,得到用于治疗支气管炎的药物。
7.根据权利要求1所述的一种治疗支气管炎的药物的服用方法,其特征在于:服用方法为饭前或饭后服用,成人每次服用量相当于生药量0.5~1g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110673933.7A CN113288969A (zh) | 2021-06-17 | 2021-06-17 | 一种治疗支气管炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110673933.7A CN113288969A (zh) | 2021-06-17 | 2021-06-17 | 一种治疗支气管炎的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113288969A true CN113288969A (zh) | 2021-08-24 |
Family
ID=77328643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110673933.7A Pending CN113288969A (zh) | 2021-06-17 | 2021-06-17 | 一种治疗支气管炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113288969A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840719A (zh) * | 2015-05-15 | 2015-08-19 | 孟智琴 | 一种治疗支气管炎的药物 |
-
2021
- 2021-06-17 CN CN202110673933.7A patent/CN113288969A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840719A (zh) * | 2015-05-15 | 2015-08-19 | 孟智琴 | 一种治疗支气管炎的药物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104940881A (zh) | 一种用于治疗慢性萎缩性胃炎的中药制剂及其制备方法 | |
CN103341092B (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN103751579A (zh) | 治疗鼻咽癌放疗引起口腔粘膜炎的药物组合物及其制备方法 | |
CN103301353B (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN103285284B (zh) | 一种治疗老年性阴道炎的药物组合物 | |
CN104436145A (zh) | 一种预防和/或治疗过敏性鼻炎及过敏性哮喘的药物组合物 | |
CN107970388A (zh) | 一种用于治疗咽炎的药物组合物、制剂及其制备方法、应用 | |
CN104840737B (zh) | 具有补气润肺作用的中药组合物及其制备方法和应用 | |
CN113288969A (zh) | 一种治疗支气管炎的药物及其制备方法 | |
CN105833055A (zh) | 一种治疗“三高”的中药组合物、其制备方法和应用 | |
CN104147270A (zh) | 治疗急性肝炎的中药组合物 | |
CN108030887A (zh) | 一种用于治疗小儿咳嗽变异性哮喘的中药糖浆剂 | |
CN109172729A (zh) | 一种清肺膏及其制备方法 | |
CN104491416B (zh) | 一种用于治疗糖尿病的中药组合物 | |
CN107468849A (zh) | 一种治疗慢性肾功能衰竭的药物及其制备方法 | |
CN1951494B (zh) | 一种治疗外感风寒的中药复方制剂及其制备方法 | |
CN101991730A (zh) | 一种治疗支气管哮喘抗复发的中药复方制剂及其制备方法 | |
CN106389589A (zh) | 一种具有止咳化痰功效的药物 | |
CN104784567B (zh) | 一种治疗泌尿系感染的药物组合物 | |
CN105168860A (zh) | 一种治疗小儿哮喘的中药组合物及其制备方法 | |
CN105194545B (zh) | 一种治疗哮喘的中药组合物 | |
CN106138687A (zh) | 一种防治肾虚型哮喘的中药组合物 | |
CN104189314A (zh) | 一种治疗痰浊阻遏证高血脂的药物组合物 | |
CN114984179A (zh) | 一种治疗或预防米格列奈不良反应的组合物及其制备方法和应用 | |
CN103463403B (zh) | 小儿哮喘用药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210824 |
|
RJ01 | Rejection of invention patent application after publication |